Biomerieux SA (BIM) - Total Liabilities
Based on the latest financial reports, Biomerieux SA (BIM) has total liabilities worth €1.47 Billion EUR (≈ $1.72 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore BIM long-term investment intensity to see how much of total assets are deployed in long-term investments.
Biomerieux SA - Total Liabilities Trend (2005–2025)
This chart illustrates how Biomerieux SA's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of Biomerieux SA.
Biomerieux SA Competitors by Total Liabilities
The table below lists competitors of Biomerieux SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
DISCOVERY LTD(UNSP.ADR)/3
F:D3H0
|
Germany | €288.99 Billion |
|
Orion Oyj B
HE:ORNBV
|
Finland | €726.20 Million |
|
Primerica Inc
NYSE:PRI
|
USA | $12.16 Billion |
|
UNICHARM CORP. SP.ADR 1
F:UN41
|
Germany | €331.92 Billion |
|
Alpha Services and Holdings S.A.
AT:ALPHA
|
Greece | €64.85 Billion |
|
ENN Ecological Holdings Co Ltd
SHG:600803
|
China | CN¥74.94 Billion |
|
Chongqing Rural Commercial Bank Co
SHG:601077
|
China | CN¥1.53 Trillion |
|
Engie Brasil Energia S.A.
SA:EGIE3
|
Brazil | R$42.91 Billion |
Liability Composition Analysis (2005–2025)
This chart breaks down Biomerieux SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Biomerieux SA's balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.29 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biomerieux SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biomerieux SA (2005–2025)
The table below shows the annual total liabilities of Biomerieux SA from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €1.47 Billion ≈ $1.72 Billion |
-5.79% |
| 2024-12-31 | €1.56 Billion ≈ $1.82 Billion |
+3.45% |
| 2023-12-31 | €1.51 Billion ≈ $1.76 Billion |
-2.38% |
| 2022-12-31 | €1.54 Billion ≈ $1.80 Billion |
+7.10% |
| 2021-12-31 | €1.44 Billion ≈ $1.69 Billion |
-0.35% |
| 2020-12-31 | €1.45 Billion ≈ $1.69 Billion |
-5.29% |
| 2019-12-31 | €1.53 Billion ≈ $1.79 Billion |
+1.66% |
| 2018-12-31 | €1.50 Billion ≈ $1.76 Billion |
+19.88% |
| 2017-12-31 | €1.25 Billion ≈ $1.47 Billion |
-10.96% |
| 2016-12-31 | €1.41 Billion ≈ $1.65 Billion |
+10.74% |
| 2015-12-31 | €1.27 Billion ≈ $1.49 Billion |
+6.65% |
| 2014-12-31 | €1.19 Billion ≈ $1.39 Billion |
+28.25% |
| 2013-12-31 | €929.30 Million ≈ $1.09 Billion |
+46.81% |
| 2012-12-31 | €633.00 Million ≈ $740.04 Million |
-3.92% |
| 2011-12-31 | €658.80 Million ≈ $770.21 Million |
+39.40% |
| 2010-12-31 | €472.60 Million ≈ $552.52 Million |
+4.26% |
| 2009-12-31 | €453.30 Million ≈ $529.96 Million |
-9.48% |
| 2008-12-31 | €500.80 Million ≈ $585.49 Million |
+26.11% |
| 2007-12-31 | €397.10 Million ≈ $464.25 Million |
+3.93% |
| 2006-12-31 | €382.10 Million ≈ $446.72 Million |
-6.26% |
| 2005-12-31 | €407.60 Million ≈ $476.53 Million |
-- |
About Biomerieux SA
bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; … Read more